| Identification | Back Directory | [Name]
[1,1′-Biphenyl]-4-sulfonamide, N-[1,2,3,4-tetrahydro-1-(methylsulfonyl)-7-quinolinyl]- | [CAS]
1209698-02-1 | [Synonyms]
[1,1′-Biphenyl]-4-sulfonamide, N-[1,2,3,4-tetrahydro-1-(methylsulfonyl)-7-quinolinyl]- | [Molecular Formula]
C22H22N2O4S2 | [MOL File]
1209698-02-1.mol | [Molecular Weight]
442.55 |
| Hazard Information | Back Directory | [Uses]
NLRP3-IN-41 (compd S-9) is an orally active and brain-penetrant NLRP3 inhibitor with anti-inflammatory activities, anti-neuroinflammatory effect and without obvious cytotoxicity. NLRP3-IN-41 inhibits the priming and activation stages of the NLRP3 inflammasome and can be used for inflammasome-related diseases research[1]. | [in vivo]
NLRP3-IN-41 (40, 80 mg/kg, i.g., 10 days) attenuates the symptoms of DSS-induced colitis in C57BL/6 and ICR mice[1].
| [IC 50]
NLRP3 | [References]
[1] Yang F, et al. Identification and Validation of PKR as a Direct Target for the Novel Sulfonamide-Substituted Tetrahydroquinoline Nonselective Inhibitor of the NLRP3 Inflammasome. J Med Chem. 2024 Jun 10. DOI:10.1021/acs.jmedchem.4c00343 |
|
|